Advanced Tissue Sciences
This article was originally published in The Gray Sheet
Executive Summary
La Jolla-based firm completes $20 mil. private placement covering the sale of 3.5 mil. shares of unregistered stock to the State of Wisconsin Investment Board. ATS filed a PMA with FDA on Aug. 25 for its Dermagraft wound dressing to treat diabetic foot ulcers (1"The Gray Sheet" Aug. 28, 2000, p. 19), three months after competitor Organogenesis received approval for its Apligraf product. Dermagraft will be marketed by Smith & Nephew